Botanix Pharmaceuticals (ASX:BOT) clinical trial update
16 Dec 2019 - Botanix Pharmaceuticals Limited (ASX:BOT) Founder Matthew Callahan talks about the company's Phase 2 US trial results for severe acne, plans for its Phase 3 trails, including FDA input, its Phase 2 atopic dermatitis study, and what investors can expect over the next 6 months.